HUMAN CONJUNCTIVA CELLULAR CULTURE CHANG ATCC-CCL 20.2 FOR PREVENTION OF THE PHENOMENON OF TOXICITY OF EYE INSTILLATION IN CASE OF THE JOINT APPLICATION OF MEDICINAL DRUGS Russian patent published in 2018 - IPC C12N5/71 G01N33/50 G01N33/53 

FIELD: biotechnologies.

SUBSTANCE: invention refers to biotechnology. Specifically, the invention refers to preventing the phenomenon of enhancing the toxicity of ocular instillations when a combination of drugs is jointly applied. Conjunctiva cell cultures are used, while selecting the optimal concentrations of eye preparations by means of evaluating the metabolic activity of the conjunctiva cell culture qualitatively through a morphological evaluation using visual control and quantitatively using the MTT test. Assessment is carried out in case of influence of these eye preparations or their combinations in different concentrations. Production of cytokines is evaluated in comparison with the transcription level control after 48 hours of incubation with these eye preparations or of the combination thereof at the selected concentration. Non-processed conjunctiva cell culture is used as the control means. Increase in cytokine production indicates the absence of the increase in the toxicity of eye instillations during the joint use of drugs, which allows the use of the proven combination of drugs for the treatment of inflammatory diseases of the conjunctiva and of the cornea.

EFFECT: invention can be used in order to prevent the phenomenon of enhancing the toxicity of ocular instillations, when the combination of drugs is jointly applied.

5 cl, 3 dwg, 1 ex, 3 tbl